Bicalutamide‐Associated Fulminant Hepatotoxicity

@article{OBryant2008BicalutamideAssociatedFH,
  title={Bicalutamide‐Associated Fulminant Hepatotoxicity},
  author={Cindy L. O’Bryant and Thomas W Flaig and Kenneth J Utz},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2008},
  volume={28}
}
Bicalutamide is a nonsteroidal antiandrogen used extensively during the start of androgen deprivation therapy with a luteinizing hormone‐releasing hormone agonist to reduce occurrence of the symptoms of tumor flare in patients with metastatic prostate carcinoma. The most common adverse effects of bicalutamide are induced by its pharmacologic property of competitive androgen receptor blockade and include gynecomastia, hot flashes, fatigue, and decreased libido. Although not as common, increases… Expand
Bicalutamide-induced hepatotoxicity: A rare adverse effect
TLDR
An 81-year-old African American male with metastatic prostate neoplasm presented with nonspecific symptoms along with jaundice of 1-day duration and bicalutamide was discontinued and he showed improvement of clinical and laboratory abnormalities within days. Expand
Atypical onset of bicalutamide-induced liver injury.
TLDR
A case of hepatotoxicity secondary to bicalutamide use is reported, in this case, hepatic injury occurred 5 mo after treatment initiation, based on this rare case of delayed liver injury. Expand
Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect
TLDR
The migratory polyarthralgia was attributed to bicalutamide due to the absence of other etiological factors and the disappearance of symptoms after discontinuation of the drug, which is the first published case report of migratory arthralgian injury and concomitant liver injury attributed to the drug. Expand
Adverse Effects of Hormones and Hormone Antagonists on the Liver
TLDR
Of the antithyroid drugs, propylthiouracil has attracted recent scrutiny for its hepatotoxic potential in children and is no longer recommended as a first-line drug in this age group. Expand
Targets to treat androgen excess in polycystic ovary syndrome
TLDR
The authors review the potential targets and new drugs to treat androgen excess in PCOS, a common androgen disorder in reproductive-aged women who suffer from cardiometabolic risk even without treatment. Expand
Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity.
TLDR
The results are compatible with the concept that flutamide targets hepatic mitochondria and exerts oxidant stress that can lead to overt hepatic injury in the presence of an underlying mitochondrial abnormality. Expand
Drug-induced liver injury: what was new in 2008?
TLDR
As in past years, 2008 was replete with publications dealing with virtually all facets of DILI, including updated incidence and prevalence data, as well as the latest information regarding mechanisms of liver injury. Expand
Thymic Involution: Where Endocrinology Meets Immunology
TLDR
It is predicted that abnormalities in both T and B lymphocytes underlie the loss of cellular and humoral capacity, respectively and surgical or chemical castration blocks sex steroids resulting in profound rejuvenation of the immune system. Expand
The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways
TLDR
The role of nuclear receptors is reviewed and their importance with links between NR examined to identify plausible putative AOPs are identified. Expand
Nonsurgical management of hyperadrenocorticism in ferrets.
TLDR
The medical management of urinary obstruction caused by prostatic enlargement and nonregenerative anemia caused by hyperestrogenism are discussed in this article. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Fatal and Nonfatal Hepatotoxicity Associated with Flutamide
TLDR
This article summarizes reports submitted to the Food and Drug Administration of patients with hepatotoxicity that may have been caused by flutamide and reviews reports that originated in domestic patient care settings. Expand
Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.
  • Mcleod
  • Medicine
  • The oncologist
  • 1997
TLDR
Bicalutamide appears to have some advantage over flutamide and nilutamide in terms of tolerability, and the reverse is true for hot flashes, which are a side effect of castration. Expand
Flare Associated with LHRH-Agonist Therapy.
TLDR
Evidence suggests that 1) advanced disease should be blocked; 2) blockade should probably include an antiandrogen beginning about 1 week prior to administration of the LHRH-agonist; and 3) that patients without advanced disease but with very high PSA levels should be considered for flare blockade. Expand
Worldwide activity and safety of bicalutamide: a summary review.
TLDR
Because it is effective and offers better tolerability than flutamide, bicalutamide represents a valid first choice for antiandrogen therapy in combination with castration for the treatment of patients with advanced prostate cancer. Expand
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
TLDR
Data is presented on the tolerability of the antiandrogens, both steroidal (cyproterone acetate; CPA) and non-steroidal (bicalutamide, flUTamide, nilutamide), across all stages of hormone-responsive prostate cancer. Expand
Microscopic Polyangiitis Complicated by the Development of Prostate Cancer and Flutamide-induced Hepatitis
TLDR
It is suggested that patients with vasculitis or other autoimmune disorders should avoid prolonged use of cyclophosphamide and other cytotoxic drugs in order to minimize long-term adverse effects, and the risk of cancer is by far the most important. Expand
Hepatotoxicity Induced by Antiandrogens: A Review of the Literature
TLDR
Although there are differences in the clinical features of hepatotoxicity induced by steroidal and nonsteroidal antiandrogens, these do not predict which patients will develop hepatot toxicity during treatment or evolution. Expand
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
TLDR
The bicalutamide, due to its better tolerability profile, together with its once-daily oral administration regimen, could be considered the antiandrogen of first choice in the treatment of prostatic cancer. Expand
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
  • D. Gillatt
  • Medicine
  • Journal of Cancer Research and Clinical Oncology
  • 2006
TLDR
The available evidence indicates that the different antiandrogens should not be regarded as equivalents in clinical practice and so the choice of treatment for patients with prostate cancer should be made on an individual basis. Expand
Flutamide hepatotoxicity.
TLDR
Flutamide is a potent hepatotoxin in certain patients and before beginning use of this drug patients should be instructed to report immediately to physicians any episodes of nausea, vomiting, fatigue and jaundice so that flutamide can be promptly discontinued to avoid progression of possible liver injury. Expand
...
1
2
3
...